Moderna Inc. (NASDAQ: MRNA) Quarterly Earnings Preview

  • Earnings per Share (EPS) Prediction: Wall Street analysts forecast an EPS of -$2.92, marking a 4.9% improvement year-over-year despite expected revenue decline.
  • Revenue Decline: Anticipated revenue of $115.3 million, a 24% decrease, primarily due to reduced demand for Moderna's COVID-19 vaccine.
  • Financial Metrics and Ratios: Moderna faces challenges with a negative P/E ratio of -3.02 and a strong current ratio of 3.67.

Moderna Inc. (NASDAQ: MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on May 1, 2025, Wall Street analysts predict an earnings per share (EPS) of -$2.92. This represents a 4.9% improvement from the previous year, despite a projected revenue decline of 24% to $115.3 million.

The anticipated revenue decline is primarily due to reduced demand for Moderna's COVID-19 vaccine, with expected sales of $112 million. This decrease is significant compared to previous years when the vaccine was in high demand. Additionally, the company's RSV vaccine, mResvia, is expected to contribute minimally to sales, with an estimated $10 million. Investors will be keen to hear updates on Moderna's pipeline during the earnings report.

Over the past month, analysts have slightly adjusted the consensus EPS estimate downward by 0.1%. These revisions are important as they can influence investor reactions and short-term stock price movements. In the previous quarter, Moderna exceeded earnings estimates by 7.06%, but there is concern that the company may not achieve an earnings beat this time. The Zacks Consensus Estimate predicts a quarterly loss of $2.91 per share.

Moderna's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -3.02, indicating negative earnings. The price-to-sales ratio is about 3.34, suggesting investors are willing to pay $3.34 for every dollar of sales. The enterprise value to sales ratio is approximately 2.96, providing insight into the company's valuation relative to its revenue.

Despite these challenges, Moderna maintains a strong current ratio of about 3.67, indicating a solid ability to cover short-term liabilities with short-term assets. The debt-to-equity ratio is relatively low at 0.065, reflecting a conservative approach to leveraging debt. Investors will closely monitor the earnings call for management's discussion on the sustainability of any immediate price changes and future earnings expectations.

Symbol Price %chg
207940.KS 1009000 0.59
068270.KS 168900 5.03
196170.KQ 392500 5.1
091990.KQ 75900 0
MRNA Ratings Summary
MRNA Quant Ranking
Related Analysis

Moderna Inc. (NASDAQ: MRNA) Quarterly Earnings Preview

  • Earnings per Share (EPS) Prediction: Wall Street analysts forecast an EPS of -$2.92, marking a 4.9% improvement year-over-year despite expected revenue decline.
  • Revenue Decline: Anticipated revenue of $115.3 million, a 24% decrease, primarily due to reduced demand for Moderna's COVID-19 vaccine.
  • Financial Metrics and Ratios: Moderna faces challenges with a negative P/E ratio of -3.02 and a strong current ratio of 3.67.

Moderna Inc. (NASDAQ: MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on May 1, 2025, Wall Street analysts predict an earnings per share (EPS) of -$2.92. This represents a 4.9% improvement from the previous year, despite a projected revenue decline of 24% to $115.3 million.

The anticipated revenue decline is primarily due to reduced demand for Moderna's COVID-19 vaccine, with expected sales of $112 million. This decrease is significant compared to previous years when the vaccine was in high demand. Additionally, the company's RSV vaccine, mResvia, is expected to contribute minimally to sales, with an estimated $10 million. Investors will be keen to hear updates on Moderna's pipeline during the earnings report.

Over the past month, analysts have slightly adjusted the consensus EPS estimate downward by 0.1%. These revisions are important as they can influence investor reactions and short-term stock price movements. In the previous quarter, Moderna exceeded earnings estimates by 7.06%, but there is concern that the company may not achieve an earnings beat this time. The Zacks Consensus Estimate predicts a quarterly loss of $2.91 per share.

Moderna's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -3.02, indicating negative earnings. The price-to-sales ratio is about 3.34, suggesting investors are willing to pay $3.34 for every dollar of sales. The enterprise value to sales ratio is approximately 2.96, providing insight into the company's valuation relative to its revenue.

Despite these challenges, Moderna maintains a strong current ratio of about 3.67, indicating a solid ability to cover short-term liabilities with short-term assets. The debt-to-equity ratio is relatively low at 0.065, reflecting a conservative approach to leveraging debt. Investors will closely monitor the earnings call for management's discussion on the sustainability of any immediate price changes and future earnings expectations.

Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector

  • Moderna's consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from analysts.
  • The company reported a higher-than-expected revenue of $1 billion for the fourth quarter but faced a GAAP net loss of $1.1 billion.
  • Moderna is developing new products, including a next-generation COVID vaccine, with a revenue forecast between $1.5 billion and $2.5 billion for 2025.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. The company is navigating a challenging period as it transitions from its COVID-19 vaccine success to introducing new products. Competitors in the biotech sector include Amgen, CRISPR Therapeutics, Sarepta Therapeutics, and Vertex Pharmaceuticals.

Over the past year, Moderna's consensus price target has seen a significant decline. A year ago, analysts set the average price target at $119.26, but it has since dropped to $47.5. This shift indicates a more cautious outlook from analysts, possibly due to market conditions and company performance.

Despite reporting higher-than-expected revenue of $1 billion for the fourth quarter, Moderna faced a GAAP net loss of $1.1 billion. This loss includes $200 million in non-cash charges related to manufacturing resizing. The decrease in demand for its COVID vaccine has impacted the company's financial performance.

Looking forward, Moderna anticipates its 2025 revenue to range between $1.5 billion and $2.5 billion. The company is also working on new products, including a next-generation COVID vaccine, an RSV vaccine, and a flu/COVID combination vaccine. These developments could influence future analyst sentiment.

Deutsche Bank analyst Emmanuel Papadakis has set a price target of $155 for Moderna, reflecting optimism in the company's potential. As Moderna prepares to announce its fourth-quarter earnings, investors are closely watching for updates on its pipeline and any impact on its stock price.

Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector

  • Moderna's consensus price target has significantly declined from $119.26 to $47.5, indicating a cautious outlook from analysts.
  • The company reported a higher-than-expected revenue of $1 billion for the fourth quarter but faced a GAAP net loss of $1.1 billion.
  • Moderna is developing new products, including a next-generation COVID vaccine, with a revenue forecast between $1.5 billion and $2.5 billion for 2025.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. The company is navigating a challenging period as it transitions from its COVID-19 vaccine success to introducing new products. Competitors in the biotech sector include Amgen, CRISPR Therapeutics, Sarepta Therapeutics, and Vertex Pharmaceuticals.

Over the past year, Moderna's consensus price target has seen a significant decline. A year ago, analysts set the average price target at $119.26, but it has since dropped to $47.5. This shift indicates a more cautious outlook from analysts, possibly due to market conditions and company performance.

Despite reporting higher-than-expected revenue of $1 billion for the fourth quarter, Moderna faced a GAAP net loss of $1.1 billion. This loss includes $200 million in non-cash charges related to manufacturing resizing. The decrease in demand for its COVID vaccine has impacted the company's financial performance.

Looking forward, Moderna anticipates its 2025 revenue to range between $1.5 billion and $2.5 billion. The company is also working on new products, including a next-generation COVID vaccine, an RSV vaccine, and a flu/COVID combination vaccine. These developments could influence future analyst sentiment.

Deutsche Bank analyst Emmanuel Papadakis has set a price target of $155 for Moderna, reflecting optimism in the company's potential. As Moderna prepares to announce its fourth-quarter earnings, investors are closely watching for updates on its pipeline and any impact on its stock price.

Moderna Inc. (NASDAQ:MRNA) Quarterly Earnings Preview

  • Analysts project a significant decline in earnings per share (EPS) and revenue for Moderna, with EPS expected to be around -$2.65 and revenue projected at approximately $941 million.
  • Despite a 66% decrease in revenue compared to the same quarter last year, Moderna maintains a strong current ratio of 4.39, indicating good short-term financial health.
  • Investors are looking forward to updates on Moderna's pipeline, including the recently FDA-approved RSV vaccine, mResvia, during the earnings call.

Moderna Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on February 14, 2025, analysts are closely watching its financial performance. Moderna's competitors include Pfizer and BioNTech, which also focus on mRNA-based vaccines.

Wall Street analysts estimate Moderna's earnings per share (EPS) to be -$2.86 for the quarter. However, recent projections suggest a slightly better outcome, with an expected loss of $2.65 per share. This marks a significant decline of 581.8% compared to the previous year. Despite this, there has been a 7.2% upward revision in the consensus EPS estimate over the past 30 days, as highlighted by Zacks Investment Research.

Revenue for the quarter is projected to be approximately $941 million, with some estimates slightly higher at $956 million. This represents a 66% decrease from the same quarter last year. A significant portion of Moderna's revenue is expected to come from its COVID-19 vaccine, with sales estimated at $869 million. The decline in revenue is attributed to reduced demand for the vaccine.

Moderna's financial ratios provide insight into its current situation. The company has a negative price-to-earnings (P/E) ratio of -5.29, indicating negative earnings. The price-to-sales ratio is about 2.31, suggesting investors are willing to pay $2.31 for every dollar of sales. Despite negative earnings, Moderna maintains a strong current ratio of 4.39, indicating good short-term financial health.

Investors will be keen to hear updates on Moderna's pipeline during the earnings report. The company's RSV vaccine, mResvia, which received FDA approval in May, is expected to contribute minimally to sales. The management's discussion during the earnings call will be crucial in determining the sustainability of any immediate price changes and future earnings expectations.

Moderna Inc. (NASDAQ:MRNA) Quarterly Earnings Preview

  • Analysts project a significant decline in earnings per share (EPS) and revenue for Moderna, with EPS expected to be around -$2.65 and revenue projected at approximately $941 million.
  • Despite a 66% decrease in revenue compared to the same quarter last year, Moderna maintains a strong current ratio of 4.39, indicating good short-term financial health.
  • Investors are looking forward to updates on Moderna's pipeline, including the recently FDA-approved RSV vaccine, mResvia, during the earnings call.

Moderna Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on February 14, 2025, analysts are closely watching its financial performance. Moderna's competitors include Pfizer and BioNTech, which also focus on mRNA-based vaccines.

Wall Street analysts estimate Moderna's earnings per share (EPS) to be -$2.86 for the quarter. However, recent projections suggest a slightly better outcome, with an expected loss of $2.65 per share. This marks a significant decline of 581.8% compared to the previous year. Despite this, there has been a 7.2% upward revision in the consensus EPS estimate over the past 30 days, as highlighted by Zacks Investment Research.

Revenue for the quarter is projected to be approximately $941 million, with some estimates slightly higher at $956 million. This represents a 66% decrease from the same quarter last year. A significant portion of Moderna's revenue is expected to come from its COVID-19 vaccine, with sales estimated at $869 million. The decline in revenue is attributed to reduced demand for the vaccine.

Moderna's financial ratios provide insight into its current situation. The company has a negative price-to-earnings (P/E) ratio of -5.29, indicating negative earnings. The price-to-sales ratio is about 2.31, suggesting investors are willing to pay $2.31 for every dollar of sales. Despite negative earnings, Moderna maintains a strong current ratio of 4.39, indicating good short-term financial health.

Investors will be keen to hear updates on Moderna's pipeline during the earnings report. The company's RSV vaccine, mResvia, which received FDA approval in May, is expected to contribute minimally to sales. The management's discussion during the earnings call will be crucial in determining the sustainability of any immediate price changes and future earnings expectations.

Piper Sandler Lowers Moderna Price Target Amid Challenges but Sees Long-Term Potential

Piper Sandler analysts reduced their price target for Moderna (NASDAQ:MRNA) from $115 to $69 while maintaining an Overweight rating on the stock. The adjustment reflects near-term challenges but underscores the company’s long-term growth prospects.

Moderna shares recently hit a 52-week low, reaching levels not seen since the early stages of the pandemic. Contributing factors include declining COVID-19 vaccination rates, underwhelming performance from mRESVIA, and uncertainty linked to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. Despite these headwinds, the analysts view the current valuation as an attractive entry point for long-term investors.

Management reiterated its 2024 product sales guidance of $3–3.5 billion, with revenue expected to bottom out at $2.9 billion in 2025 before resuming growth. This recovery is anticipated to be driven by the launch of eight new vaccines and products by 2028. Notable launches include the next-generation COVID-19 vaccine (mRNA-1283) and mRESVIA for high-risk adults in 2025, as well as a combination flu and COVID-19 vaccine (mRNA-1083) in 2026.

While short-term sales pressures persist, Piper Sandler remains optimistic about Moderna's ability to capitalize on its innovative pipeline and long-term opportunities, justifying the continued Overweight rating despite the reduced price target.